June 1, 2010Heart
NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin
Why the study?
Does anti-PECAM scFv-uPA improve clot lysis and cerebral reperfusion compared to unconjugated uPA in a mouse model of cerebrovascular thrombosis?
Population
Mice (preclinical model of cerebrovascular thrombosis)
Comparison
Intravascular injection of recombinant construct… vs Unconjugated uPA
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
scFv-uPA enables safe targeted reperfusion in murine stroke; leaves open translation to human cerebrovascular thrombosis.
Structured PICO
Does anti-PECAM scFv-uPA improve clot lysis and cerebral reperfusion compared to unconjugated uPA in a mouse model of cerebrovascular thrombosis?
P
Population
Mice (preclinical model of cerebrovascular thrombosis)
I
Intervention
Intravascular injection of recombinant construct antiplatelet-endothelial cell adhesion molecule (PECAM) single-chain variable fragment (scFv)-urokinase-type plasminogen activator (uPA)
C
Comparator
Unconjugated uPA
O
Outcome
Clot lysis in the cerebral arterial vasculature, cerebral reperfusion, and post-thrombotic brain edemasurrogate
Targeted delivery of uPA to the cerebral endothelium via anti-PECAM scFv-uPA provides effective and safe thromboprophylaxis in a mouse model, offering a potential new strategy to prevent recurrent cerebrovascular thrombosis.
Cite This Study
Skinner et al. (2010) studied this question.